XM does not provide services to residents of the United States of America.

XM does not provide services to residents of the United States of America.
B
B

Biogen

News

Reuters - 3 days ago

U.S. Microstrategy, Snowflake, Target

U.S. RESEARCH ROUNDUP-Microstrategy, Snowflake, Target Nov 21 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Microstrategy, Snowflake and Target, on Thursday. HIGHLIGHTS * Dycom Industries Inc DY.N : D.A. Davidson raises target price to $220 from $210 * Microstrategy Inc MSTR.O : BTIG raises target price to $570 from $290 * Snowflake Inc SNOW.N : Piper Sandler raises target price to $185 from $165 * Target Corp TGT.
B
G
G
G
N
B
B
C
J
L
Reuters - 4 days ago

Sage to abandon development of neurological disorder drug after multiple failures

UPDATE 3-Sage to abandon development of neurological disorder drug after multiple failures Adds graphic, updates shares, adds company comment in paragraph 4, analyst comment in paragraph 5 By Mariam Sunny Nov 20 (Reuters) - Sage Therapeutics SAGE.O said on Wednesday it would stop the development of its experimental drug following the latest failure in a study testing it in patients with Huntington's disease, a rare neurological disorder.
B
S
Reuters - 5 days ago

U.S. STOCKS Henry Schein Inc, Palantir Technologies, Uber Technologies

U.S. STOCKS ON THE MOVE-Henry Schein Inc, Palantir Technologies, Uber Technologies Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were mixed on Monday, as investors looked ahead to earnings from AI-chip leader Nvidia following a rout the previous week on apprehensions about Donald Trump's cabinet appointments and the central bank's policy path.
B
J
N
N
T
U
U
U
G
Reuters - 6 days ago

Nasdaq top and bottom performing stocks at about 12:01 p.m. EST

BUZZ - Nasdaq top and bottom performing stocks at about 12:01 p.m. EST Nasdaq 100 .NDX Top Performers Percent Change Super Micro Computer Inc SMCI.OQ +16.9% Tesla Inc TSLA.OQ +7% Moderna Inc MRNA.OQ +6.0% Diamondback Energy Inc FANG.OQ +3.2% Advanced Micro Devices Inc AMD.OQ +3.2% Bottom Performers Percent Change Illumina Inc ILMN.OQ -2.6% Lululemon Athletica Inc LULU.OQ -2.4% NVIDIA Corp NVDA.OQ -1.4% Biogen Inc BIIB.OQ -1.2% Keurig Dr Pepper Inc KDP.OQ -1.2% The Nasdaq 100 .NDX gained 169.50 p
B
I
L
N
T
A
U
D
Reuters - 6 days ago

U.S. STOCKS Tesla Inc, Palantir Technologies and Super Micro Computer Inc

BUZZ-U.S. STOCKS ON THE MOVE-Tesla Inc, Palantir Technologies and Super Micro Computer Inc Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were mixed on Monday, as investors looked ahead to earnings from AI-chip leader Nvidia following a rout the previous week on apprehensions about Donald Trump's cabinet appointments and the central bank's policy path.
B
N
T
U
U
U
G
Reuters - 6 days ago

U.S. STOCKS Silver Miners, Intellia, Robinhood

BUZZ-U.S. STOCKS ON THE MOVE-Silver Miners, Intellia, Robinhood Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock futures were mixed on Monday as investors shifted their attention to key corporate results, particularly from AI-chip heavyweight Nvidia, after a sharp decline on Wall Street the previous week.
B
N
T
G
Reuters - 6 days ago

Biogen falls as Needham cuts to 'hold' on slow adoption of Alzheimer's drug

BUZZ-Biogen falls as Needham cuts to 'hold' on slow adoption of Alzheimer's drug ** Shares of Biogen BIIB.O fall ~1% to $158.41 before the bell ** Brokerage Needham cuts rating on BIIB to "hold" from "buy" citing no "meaningful source of upside" for the stock in the next year and a slow ramp of sales for its Alzheimer's drug Leqembi ** Needham says
B
Reuters - 6 days ago

U.S. Airbnb, Post Holdings, Syndax Pharmaceuticals

U.S. RESEARCH ROUNDUP- Airbnb, Post Holdings, Syndax Pharmaceuticals Nov 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Airbnb, Post Holdings and Syndax Pharmaceuticals, on Monday. HIGHLIGHTS * Airbnb Inc ABNB.O : D.A. Davidson raises PT to $131 from $125 * Korro Bio Inc KRRO.O : Jonestrading initiates coverage with buy rating; PT $130 * Post Holdings Inc POST.N : JP Morgan raises target price to $135 from $125 *
A
A
B
E
G
H
S
D
D
E
E
A
C
C
D
I
Reuters - 1 week ago

U.S. Applied Materials, Disney, Walmart

U.S. RESEARCH ROUNDUP-Applied Materials, Disney, Walmart Nov 15 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Applied Materials, Disney, and Walmart, on Friday. HIGHLIGHTS * Applied Materials Inc AMAT.O : Jefferies cuts target price to $180 from $210 * Cava Group Inc CAVA.N : Piper Sandler raises target price to $142 from $100 * Disney DIS.N : Piper Sandler raises target price to $115 from $95 * Nvidia Corp NVDA.O
A
B
C
F
N
T
A
F
A
A
A
H
Reuters - 1 week ago

U.S. STOCKS Talen Energy, Biogen, Ovintiv

BUZZ-U.S. STOCKS ON THE MOVE-Talen Energy, Biogen, Ovintiv Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were subdued on Thursday after monthly producer prices rose as expected, with investors awaiting Fed Chair Jerome Powell's comments later in the day for clues on the outlook for interest rates.
A
A
B
C
N
W
U
U
A
H
Reuters - 1 week ago

Biogen rises after EU regulator recommends Alzheimer's drug

BUZZ-Biogen rises after EU regulator recommends Alzheimer's drug ** Drugmaker Biogen's BIIB.O shares rise 2% to $169.14 ** European Union's drugs regulator says it recommends approval of Eisai 4523.T and Biogen's drug Leqembi in patients with early Alzheimer's disease ** In July, the drug regulator rejected Leqembi saying the risk of serious brain
B
Reuters - 1 week ago

EU regulator backs Eisai-Biogen Alzheimer's drug after initial rejection

UPDATE 3-EU regulator backs Eisai-Biogen Alzheimer's drug after initial rejection Adds analyst comment in paragraphs 7, 11 and 12 By Bhanvi Satija Nov 14 (Reuters) - The European Union's drugs regulator on Thursday recommended approval of Eisai 4523.T and Biogen's BIIB.O Leqembi for some patients with early Alzheimer's disease, reversing its initial decision from four months ago.
B
Reuters - 1 week ago

EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen

EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen Nov 14 (Reuters) - The European Union's drugs regulator on Thursday said it recommends approval of Eisai 4523.T and Biogen's BIIB.O Leqembi in patients with early Alzheimer's disease, months after the agency first rejected the treatment. Reporting by Bhanvi Satija in Bengaluru; Editin
B
Reuters - 1 week ago

U.S. Cisco, Freshpet, Nvidia

U.S. RESEARCH ROUNDUP-Cisco, Freshpet, Nvidia Nov 14 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cisco, Freshpet and Nvidia, on Thursday. HIGHLIGHTS * Cisco CSCO.O : Jefferies raises target price to $66 from $53 * Freshpet Inc FRPT.O : Oppenheimer raises target price to $180 from $155 * ICU Medical Inc ICUI.O : Raymond James raises target price to $205 from $190 * Kronos Bio Inc KRON.O : TD Cowen cuts to hold fro
A
A
B
C
N
A
A
A
Reuters - 3 weeks ago

Brainy efforts underway, but still some way to go for neuro drug developers

LIVE MARKETS-Brainy efforts underway, but still some way to go for neuro drug developers Main U.S. indexes sharply higher; Nasdaq, Dow up 1.3% Cons Disc leads S&P sector gainers; Utilities sole loser Euro STOXX 600 index up 1.3% Dollar rises; gold edges up; crude, up >1%, bitcoin up 0.4% U.S. 10-Year Treasury yield edges up to ~4.33% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters.
A
B
R
U
U
Reuters - 3 weeks ago

U.S. Altair Engineering, Brinker International, Meta

U.S. RESEARCH ROUNDUP-Altair Engineering, Brinker International, Meta Oct 31 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Altair Engineering, Brinker International and Meta, on Thursday. HIGHLIGHTS * Altair Engineering Inc ALTR.O : Needham cuts to hold from buy * Blackbaud Inc BLKB.O : Baird cuts to neutral from outperform * Brinker International Inc EAT.N : JP Morgan cuts to neutral from overweight * Comstock Res
A
A
B
B
C
C
E
G
I
M
S
V
V
A
A
C
K
E
C
Reuters - 4 weeks ago

Biogen Inc reports results for the quarter ended in September 30 - Earnings Summary

Biogen Inc reports results for the quarter ended in September 30 - Earnings Summary Biogen Inc BIIB.OQ reported quarterly adjusted earnings of $4.08​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of $4.36. The mean expectation of twenty nine analysts for the quarter was for earnings of $3.79 per share.
B
Reuters - 4 weeks ago

Biogen lifts annual profit forecast as new treatments boost earnings

UPDATE 2-Biogen lifts annual profit forecast as new treatments boost earnings Updates shares, adds analyst comment in paragraph 4, CEO comment in paragraph 7 and graphic By Mariam Sunny Oct 30 (Reuters) - Biogen BIIB.O raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple sclerosis drugs.
B
N
Reuters - 4 weeks ago

Biogen Q3 Adjusted EPS USD 4.08 Vs. IBES Estimate USD 3.79

BRIEF-Biogen Q3 Adjusted EPS USD 4.08 Vs. IBES Estimate USD 3.79 Oct 30 (Reuters) - Biogen Q3 revenue USD 2,500 million vs. IBES estimate USD 2,434 million. Q3 EPS USD 2.66
B
Reuters - 4 weeks ago

Biogen Says Still Sees FY Rev Down Low-Single Digit Percent, With Core Pharma Rev Roughly Flat

BRIEF-Biogen Says Still Sees FY Rev Down Low-Single Digit Percent, With Core Pharma Rev Roughly Flat Oct 30 (Reuters) - Biogen Inc BIIB.O : BIOGEN Q3 ADJUSTED EPS $4.08 VERSUS IBES ESTIMATE $3.79 BIOGEN OUTLOOK FY ADJUSTED EPS $16.10 TO $16.60 VERSUS PRIOR OUTLOOK $15.75 TO $16.25 BIOGEN FY2024 EPS VIEW $16.19, REVENUE VIEW $9.64 BILLION -- IBES DA
B

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.